This new blog explores an emerging infectious disease and how SK pharmteco can support the development and manufacture of small-molecule antiviral therapies for it.
The 2026 Ebola outbreak in the Democratic Republic of the Congo and Uganda has put an uncommon but consequential ebolavirus back into focus: Bundibugyo ebolavirus, the causative virus of Bundibugyo virus disease and a member of the species Orthoebolavirus bundibugyoense.1,2
For public health responders, the immediate priorities are clear: surveillance, rapid diagnostics, contact tracing, isolation and supportive care, infection prevention and control, safe burials, and community trust. For drug developers, the outbreak highlights a different but closely related issue. Meaningful progress has been made against Ebola disease caused by Zaire ebolavirus, including approved vaccines and monoclonal antibody therapies. But those successes do not automatically translate to Bundibugyo virus disease.
What is Bundibugyo Ebolavirus?
Bundibugyo virus was first identified during a 2007 outbreak in western Uganda. Genetic analysis showed that it was distinct from previously known ebolaviruses, differing by more than 30% at the genome level from recognized species at the time.3 That divergence matters because ebolavirus countermeasures are often highly species-specific. Viral genetic and antigenic differences can affect diagnostic assay design, vaccine antigen selection, antibody binding, neutralization potency, and assumptions about cross-protection.
Clinically, Bundibugyo virus disease can resemble other forms of Ebola disease. Early symptoms may include fever, fatigue, muscle pain, headache, and sore throat, followed by gastrointestinal symptoms such as vomiting and diarrhea. Severe cases can involve shock, organ dysfunction, and bleeding in some patients. CDC notes that symptoms may appear 2 to 21 days after exposure, with many patients developing symptoms around 8 to 10 days after contact with the virus.
Bundibugyo virus disease has historically appeared less lethal than Ebola disease caused by Zaire ebolavirus, but “less lethal” should not be confused with low risk.2 CDC reports that the two previous known Bundibugyo outbreaks, in Uganda in 2007 and DRC in 2012, had death rates of approximately 25% and 50%, respectively.4 In the 2026 outbreak, reported fatality estimates continue to evolve as surveillance expands, case confirmation improves, and deaths that occurred before outbreak declaration are investigated.
The 2026 Outbreak Has Changed the Preparedness Conversation
When the outbreak was first confirmed in May 2026, it was already notable because Bundibugyo virus disease had been recorded only rarely. Since then, the event has escalated into a major regional emergency. WHO confirmed that the outbreak affected both DRC and Uganda, and the WHO Director-General determined in May 2026 that the epidemic constituted a Public Health Emergency of International Concern.
By early July 2026, the outbreak had become the largest recorded Bundibugyo virus disease outbreak. ECDC reported that, as of July 6, the outbreak was affecting DRC and Uganda, with DRC reporting 1,561 confirmed cases and 506 confirmed deaths based on data through July 4. Other regional surveillance summaries reported 1,708 laboratory-confirmed cases and 580 deaths as of July 6. Because case counts are changing quickly, the most accurate way to discuss the outbreak is to date any numbers and acknowledge that surveillance updates may revise totals.
The outbreak context also matters. WHO describes the response environment as complex, with humanitarian pressures, insecurity, population movement, and cross-border transmission risk. Those conditions affect every element of countermeasure deployment: diagnostic access, sample transport, patient referral, clinical trial execution, cold-chain management, staff safety, and community engagement.
Why Existing Ebola Products Are Not Enough
The most important development reality is straightforward since currently approved Ebola vaccines and therapeutics are primarily designed for Ebola disease caused by Orthoebolavirus zairense, not Bundibugyo virus disease.
CDC states that Bundibugyo virus has no approved treatments as of this writing.2 CDC also notes that there are two FDA-approved treatments for Ebola disease caused by Orthoebolavirus zairense, but that other orthoebolaviruses, including Bundibugyo, do not have approved treatments. WHO similarly reports that there are no licensed therapeutics or vaccines specifically approved for the prevention or treatment of Bundibugyo virus disease.
This distinction is central to the drug development story. For example, a licensed Ebola vaccine based on a recombinant vesicular stomatitis virus platform is approved for Ebola disease caused by Zaire ebolavirus. WHO has reviewed its potential role in the 2026 Bundibugyo outbreak but concluded that evidence for cross-protection against Bundibugyo virus remains limited and inconclusive. WHO recommends that the product should not be used for Bundibugyo virus disease outside carefully designed research settings.
That does not mean the field is starting from zero. It means the field is being forced to adapt proven platform concepts to a less-developed viral target.
The Countermeasure Pipeline Is Now Moving
The 2026 outbreak has accelerated evaluation of several candidate countermeasures evaluated, creating a clear translational challenge for drug developers.1
For treatment, WHO advisory groups prioritized three candidates for clinical evaluation in confirmed Bundibugyo virus disease: the monoclonal antibodies MBP134 and maftivimab, and the antiviral remdesivir. WHO also recommended evaluation of combination therapy using a monoclonal antibody plus remdesivir. For post-exposure prophylaxis among contacts of confirmed or probable cases, WHO prioritized obeldesivir, an oral antiviral candidate, while noting that this strategy depends heavily on effective contact tracing.
A major development occurred on July 2, 2026, when enrollment opened for a new trial to determine if existing therapies can improve survival in patients with Bundibugyo virus disease. This could prove important because it allows additional investigational therapies to be added as evidence and product availability evolve.
On the vaccine side, WHO advisory groups identified a single-dose rVSV Bundibugyo vaccine candidate as the most promising candidate, although WHO indicated that additional development time would likely be needed before efficacy assessment in a clinical trial.5 WHO also reviewed another being developed in a joint collaboration between a British university and a government institute, as a candidate that could potentially become available sooner for efficacy assessment, pending additional animal data. Additionally, computational vaccine design work has also proposed multi-epitope approaches, though experimental validation remains necessary before such concepts can move toward clinical relevance.6
These programs reflect two complementary preparedness strategies. One is species-specific protection, using Bundibugyo glycoprotein-based vaccine constructs or Bundibugyo-directed antibody products. The other is broader filovirus coverage, using antibodies, antivirals, or multivalent vaccine designs that may retain activity across multiple ebolavirus species.
Diagnostics Are Part of the Countermeasure Gap
The countermeasure discussion should not focus only on vaccines and therapeutics. Diagnostics are equally important.
On July 2, 2026, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing. The test detects viral genetic material in blood samples and is intended to support rapid and accurate confirmation of infection.
This is a major operational milestone. In an Ebola outbreak, faster diagnosis can shorten the time between symptom onset, isolation, supportive care, contact tracing, and trial enrolment. It also supports cleaner epidemiologic data, which is essential for assessing whether interventions are working.
For developers and manufacturers, the diagnostic update reinforces a broader point: outbreak readiness depends on coordinated toolsets. A vaccine candidate, monoclonal antibody, antiviral, or clinical trial cannot function effectively without reliable case identification and field-ready testing pathways.
The Development Bottleneck is Not Only Discovery
When an outbreak emerges, speed depends on more than a promising antigen, antibody, or antiviral mechanism. Developers also need to complete a development and manufacturing path:
- For vaccines, this may include scalable viral vector production, cell substrate control, upstream and downstream process development, potency assays, adventitious agent testing, formulation, stability, fill-finish capacity, and cold-chain strategy.
- For monoclonal antibodies, it includes cell-line development or platform expression systems, purification, viral clearance validation, aggregation control, formulation, release testing, and clinical supply planning.
- For small-molecule antivirals, it includes API route readiness, impurity control, scale-up, oral formulation, packaging, stability, and distribution.
In outbreak-driven indications, these technical requirements collide with unusual constraints. Demand is uncertain. Trial locations may be remote or insecure. Cold-chain infrastructure may be limited. Ethical trial designs must be developed during active transmission. Product availability may need to align with rapidly changing epidemiology. Regulatory submissions may need to move quickly while still meeting evidence and quality expectations.
That is where experienced CDMO support becomes strategic. A CDMO with integrated development and GMP manufacturing capabilities can help convert a promising candidate into a deployable investigational countermeasure by supporting process development, optimization, analytical methods, formulation, stability, tech transfer, documentation, clinical supply, and readiness for accelerated review.
The question surrounding Bundibugyo virus disease is not simply whether science can identify plausible candidates but as importantly, whether the field can generate usable, quality-controlled supply fast enough to evaluate those candidates during the outbreak window.
What Drug Developers Should Watch Next
The 2026 Bundibugyo outbreak is likely to accelerate investment across several medical countermeasure categories:
First, species-specific and multivalent filovirus vaccines will attract more attention. A preparedness portfolio that covers Zaire, Sudan, Bundibugyo, and Marburg viruses is more resilient than one built around a single ebolavirus species.
Second, broadly reactive monoclonal antibodies will remain a priority. Antibody cocktails or engineered antibodies that retain activity across multiple ebolaviruses could reduce the strain-specific vulnerability exposed by Bundibugyo.
Third, small-molecule antivirals deserve renewed focus. Two small molecule antivirals are being evaluated because antiviral products may offer operational advantages, including broader activity potential and, in the case of oral agents, easier use for post-exposure prophylaxis.
Fourth, platform trial infrastructure is becoming part of outbreak readiness. The PARTNERS trial shows how pre-positioned protocols, governance, data systems, and clinical networks can allow therapeutic evaluation to begin during an active emergency rather than after the outbreak has passed.
Fifth, diagnostic readiness is now a visible part of the development equation. The WHO Emergency Use Listing for a Bundibugyo molecular test shows how regulatory-grade diagnostics can directly support containment, patient care, and therapeutic evaluation.
Finally, CMC playbooks will become a competitive differentiator. Sponsors with prebuilt manufacturing templates, release assays, stability strategies, comparability plans, and clinical supply processes will be better positioned when public health agencies need investigational products rapidly.7
A Preparedness Lesson for the CDMO Ecosystem
Bundibugyo virus is a reminder that “Ebola preparedness” cannot be treated as a single-virus category. The success of Zaire ebolavirus countermeasures is real, but it does not solve Bundibugyo, Sudan, or other filovirus threats by default.
For drug developers, that means platform adaptability, antigenic specificity, broad reactivity, diagnostic alignment, and manufacturing readiness must advance together. A candidate that looks strong in preclinical testing still needs a practical path to quality-controlled clinical supply that can scale under pressure. Clinical trials cannot succeed without reliable diagnostics and treatment-center infrastructure. Therefore, vaccine strategies cannot be judged only by immunogenicity; they must also account for dose regimen, time to protection, storage, delivery, and field implementation.
The companies best positioned for the next phase of filovirus preparedness will not only discover promising candidates. They will build development paths that can operate under pressure.
In that environment, the right CDMO can help bridge the gap between urgent science and usable supply. For Bundibugyo virus disease and future filovirus outbreaks, process, analytics, quality, documentation, and speed may determine whether a candidate remains a research asset or becomes an outbreak-ready medical countermeasure.
References
- World Health Organization, Ebola Outbreak — DRC 2026, July 2026.
- Centers for Disease Control and Prevention, Ebola and Bundibugyo Virus Frequently Asked Questions, July 2026.
- J.S. Towner, et al., Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda, PLoS Pathog., 4, 11 (2008). doi.org/10.1371/journal.ppat.1000212
- A. MacNeil, et al., Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda, Emerging Infectious Diseases (2010). https://wwwnc.cdc.gov/eid/article/16/12/10-0627_article
- C. Woolsey, et al., A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection, Journal of Infectious Diseases, 228(7), S712 (2023).
doi.org/10.1093/infdis/jiad207
- S. Khan, et al., Design of a Novel Multi-Epitope-Based Vaccine Against Bundibugyo Ebolavirus Using Computational Approach, Med. Omics, 16,100050 (2026). doi.org/10.1016/j.meomic.2025.100050
- World Health Organization, Experts Convened by WHO Advise on Candidate Treatments and Vaccines for Ebola Disease Caused by Bundibugyo Virus , July 2026.
- World Health Organization, Patient Enrolment Begins in a Scientific Trial to Identify the First Effective Treatments for Bundibugyo Virus Disease, July 2026.
- World Health Organization. WHO Adds First Diagnostic Test for Ebola Bundibugyo Virus to its Emergency Use Listing. July 2, 2026.
- European Centre for Disease Prevention and Control, Ebola disease outbreak in the Democratic Republic of the Congo and Uganda, July 2026.
- National Institute for Communicable Diseases. Bundibugyo virus disease updates – NICD, July 2026.